Literature DB >> 11965537

Rac is activated by erythropoietin or interleukin-3 and is involved in activation of the Erk signaling pathway.

Ayako Arai1, Eiichiro Kanda, Osamu Miura.   

Abstract

Previous studies have shown that hematopoietic cytokines, including erythropoietin (Epo) and interleukin (IL)-3, activate the Ras GTPase and the downstream Raf/Erk/Elk-1 signaling pathway. Here we report that Epo or IL-3 rapidly and transiently activates Rac, a Rho family GTPase, in hematopoietic cell lines, 32D/EpoR-Wt and UT-7. The cytokine-induced activation of Rac was augmented in a 32D/EpoR-Wt clone that inducibly overexpresses the adaptor protein CrkL or the Ras guanine nucleotide exchange factor C3G, which forms a complex with CrkL. Furthermore, the Rac activation was enhanced or inhibited in cells inducibly expressing an activated Ras mutant, H-Ras61L, or a dominant negative Ras mutant, H-Ras17N, respectively. In addition, the cytokine-induced Rac activation was inhibited by a phosphatidyl-inositol 3'-kinase (PI3K) inhibitor, LY294002, which also inhibited the Erk activation. A dominant negative Rac mutant, Rac17N, also inhibited the cytokine-induced activation of Erk as well as Elk-1. On the other hand, activation of Akt downstream of PI3K was found to play an inhibitory role in cytokine activation of Erk/Elk-1. Together, these results indicate that Rac is activated by Epo or IL-3 at downstream of the Ras/PI3K pathway in parallel with Akt and plays a role in activation of the Erk/Elk-1 signaling pathway in hematopoietic cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11965537     DOI: 10.1038/sj.onc.1205346

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Targeted shRNA screening identified critical roles of pleckstrin-2 in erythropoiesis.

Authors:  Baobing Zhao; Ganesan Keerthivasan; Yang Mei; Jing Yang; James McElherne; Piu Wong; John G Doench; Gang Feng; David E Root; Peng Ji
Journal:  Haematologica       Date:  2014-04-18       Impact factor: 9.941

Review 2.  Emerging EPO and EPO receptor regulators and signal transducers.

Authors:  David Kuhrt; Don M Wojchowski
Journal:  Blood       Date:  2015-04-17       Impact factor: 22.113

3.  Repression of c-kit and its downstream substrates by GATA-1 inhibits cell proliferation during erythroid maturation.

Authors:  Veerendra Munugalavadla; Louis C Dore; Bai Lin Tan; Li Hong; Melanie Vishnu; Mitchell J Weiss; Reuben Kapur
Journal:  Mol Cell Biol       Date:  2005-08       Impact factor: 4.272

4.  Polyomavirus middle T antigen induces the transcription of osteopontin, a gene important for the migration of transformed cells.

Authors:  Kerry A Whalen; Georg F Weber; Thomas L Benjamin; Brian S Schaffhausen
Journal:  J Virol       Date:  2008-03-12       Impact factor: 5.103

5.  Osteopontin regulates actin cytoskeleton and contributes to cell proliferation in primary erythroblasts.

Authors:  Jeong-Ah Kang; Ying Zhou; Tahlia L Weis; Hui Liu; Jodie Ulaszek; Nilesh Satgurunathan; Li Zhou; Koen van Besien; John Crispino; Amit Verma; Philip S Low; Amittha Wickrema
Journal:  J Biol Chem       Date:  2008-01-03       Impact factor: 5.157

6.  Clostridium difficile toxins A and B directly stimulate human mast cells.

Authors:  Gesa K A Meyer; Anne Neetz; Gudrun Brandes; Dimitrios Tsikas; Joseph H Butterfield; Ingo Just; Ralf Gerhard
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

7.  Antineoplastic and anti-inflammatory effects of bortezomib on systemic chronic active EBV infection.

Authors:  Mayumi Yoshimori; Haruna Shibayama; Ken-Ichi Imadome; Fuyuko Kawano; Ayaka Ohashi; Miwako Nishio; Norio Shimizu; Morito Kurata; Shigeyoshi Fujiwara; Ayako Arai
Journal:  Blood Adv       Date:  2021-04-13

8.  STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target.

Authors:  Erika Onozawa; Haruna Shibayama; Honami Takada; Ken-Ichi Imadome; Sho Aoki; Mayumi Yoshimori; Norio Shimizu; Shigeyoshi Fujiwara; Takatoshi Koyama; Osamu Miura; Ayako Arai
Journal:  Oncotarget       Date:  2018-07-24

9.  P-glycoprotein is expressed and causes resistance to chemotherapy in EBV-positive T-cell lymphoproliferative diseases.

Authors:  Mayumi Yoshimori; Honami Takada; Ken-Ichi Imadome; Morito Kurata; Kouhei Yamamoto; Takatoshi Koyama; Norio Shimizu; Shigeyoshi Fujiwara; Osamu Miura; Ayako Arai
Journal:  Cancer Med       Date:  2015-07-08       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.